Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.5652W HIGH $1.96
Volume
482.00
Value Traded
579.60
Short % Float
0.05%
Days to Cover
1.0
-50.88%Week
-52.14%1 Month
-67.91%3 Month
-65.54%6 Month
-99.03%5 Year
-99.93%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.55 M
EPS (TTM)
-0.27
P/E Ratio
-
Ent. Value
-9.04 M
Total Shares
11.71 M
Float Shares
7.04 M
Insiders
39.35%
Institutions
37.16%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
SYBX Catalyst Timeline
Dated clinical, regulatory and corporate events for Synlogic, Inc.
Past FDA Catalysts and PDUFA Decisions
How SYBX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
5
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SYNB1618 Small moleculeCompletedNCT03516487 | Phenylketonuria | Phase 2 | COMPLETED | 90 | Jun 21, 2019 | ||||||
| SYNB1934 Small moleculeCompletedNCT04984525 | Phenylketonuria | Phase 1 | COMPLETED | 106 | Dec 10, 2021 | ||||||
| SYNB8802v1 Small moleculeCompletedNCT05377112 | Enteric Hyperoxaluria | Phase 1 | COMPLETED | 11 | Dec 7, 2022 | ||||||
| SYNB8802 Small moleculeCompletedNCT04629170 | Enteric Hyperoxaluria | Phase 1 | COMPLETED | 77 | Jan 17, 2023 | ||||||
| SYNB1353 Small moleculeCompletedNCT05462132 | Homocystinuria | Phase 1 | COMPLETED | 31 | Nov 27, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every SYBX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SYNB8802 | Enteric Hyperoxaluria | Phase 1b | 2022-12-15 | -38% reduction in urinary oxalate compared to placebo; -28% (-37.2, -18.2) change from baseline in urinary oxalate vs. placebo at the 1x1011 TID dose; -38% (-46.4, -28.7) change from baseline in urinary oxalate vs. placebo at the 3x1011 TID doseRead More | Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study Results include -38% reduction in urinary oxalate compared to placebo in Roux-eRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| New Enterprise Associates 14, L.P.10% Owner | BuyWarrant exercise | 2,640,845 2,640,845 held | $0.00 | 07/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SYBX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| NEA Management Company, LLC | 0.2 % (-33.3 %) | 3.27 M | 2.92 M |
Ownership Trends
SYBX Short Interest
Shares sold short, counted twice a month.
0.05%
Short % of Float
of tradable shares sold short
2.9K
Shares Sold Short
-0.7% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
89.8K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SYBX ranks across every disease it competes in
Competitive Position is a premium feature
See how SYBX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSYBX News
About Synlogic, Inc.
Headquarters301 Binney Street
Founded30-09-2015
BIOPHARMAWATCH ELITE PLUS
Trade the next SYBX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime